Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus - 14/02/14
, Nobukazu Hayashi, MD, PhD a, Kuniaki Ohara, MD a, Keiji Aoki, MSc c, Ichimaro Yamada, PhD c, Kenji Ikeda, MD, PhD b, Hiromitsu Kumada, MD, PhD b| Funding sources: None. |
|
| Disclosures: Dr Kishi has received honoraria for participation in advisory boards for Pharma International Inc and for being a speaker for Chugai, Mitsubishi Tanabe Pharma, and Sato. Dr Hayashi has been a consultant for Eisai, Galderma, and Maruho, and a speaker for Candela, Daiichi-Sankyo, Dainihon-Sumitomo, Galderma, GlaxoSmithKline. JMEC, Maruho, Pola Pharmacy, Sato, Shionogi, Tokiwa, and Torii, and has received research grants from Daiichi-Sankyo, Galderma, Maruho, Shionogi, and Mitsubishi-Tanabe Pharma. Mr Aoki and Mr Yamada have been employees of Mitsubishi Tanabe Pharma. Dr Kumada has been a speaker for MSD, Mitsubishi Tanabe Pharma. |
Vol 70 - N° 3
P. 584-586 - marzo 2014 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
